Skip to main content

Table 2 Associations between the SULT1A1 rs9282861 genotypes, adjuvant treatment and overall survival (OS)

From: SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?

Cases n HR 95% CI P § median OS (years)
chemotherapy only 76     13.0
GG or AG 62 1    11.0
AA 14 0.33 0.10 to 1.09 0.068 16.0
TAM only 65     9.2
GG or AG 47 1    8.2
AA 18 0.53 0.27 to 1.08 0.079 11.9
chemotherapy/TAM¥ 145     10.0
GG or AG 112 1    9.1
AA 33 0.50 0.29 to 0.88 0.015 13.7
  1. Abbreviations: TAM = tamoxifen
  2. § P was based on Cox proportional analysis
  3. Reference value; HRs adjusted for age and stage at diagnosis, radiation therapy, and hormone receptor status
  4. Reference value; HRs adjusted for age and stage at diagnosis, and radiation therapy
  5. ¥Four patients received chemotherapy and TAM